In Europe, biologics and biosimilars are evaluated through a lens of scientific comparability and public health responsibility. For executives, this means regulatory strategy and commercial planning are closely linked. Entering the EU market requires clarity on both. To set the foundation, the next section explains how the EU views biologics and biosimilars.
Biologics & Biosimilar Regulations in European Union
Biologics changed how serious diseases are treated in Europe. They also changed regulation. Living systems behave differently from chemicals, and the rules reflect that reality. Control, traceability, and consistency drive every regulatory decision in this space.
- Products such as Humira, Herceptin, EPO, and basal insulin are Biologics examples.
Biosimilars are developed when patents expire. They are not shortcuts. Approval depends on evidence, not intention. If the data does not support equivalence, access is denied — regardless of price advantage.
- Well-established biosimilars include infliximab, filgrastim, epoetin, and rituximab.
Biologics & Biosimilars Regulatory Authority in EU:
European Medicines Agency (EMA) acts as the single decision point for biologics and biosimilars in Europe. In the EU, biologics and biosimilars don’t go through separate approvals in each country. Companies deal with one central authority instead. EMA reviews the data, weighs the risks, and sets the direction for the entire region.
Biologics & Biosimilars Registration Process in EU:
Approval in the EU depends less on novelty and more on consistency with the already approved biologic and biosimilar products. Here is the step by step process of registration of biologics in EU:
Step 1: Preparation and Planning
Before heavy development work begins, many companies speak to the EMA. Not for permission — for clarity.
These early discussions help confirm:
- what data the agency expects
- how deep studies need to go
- where shortcuts will not be accepted
Skipping this step doesn’t stop approval, but it often creates delays later.
Step 2: Documents for submission
This phase takes the most time and effort. The dossier grows piece by piece.
Manufacturing and quality:
- Details on how the product is made, controlled, and tested
- Proof that batches remain consistent over time
- Stability results showing the product holds up under storage conditions
Similarity work:
- Side-by-side analytical comparisons with the reference biologic
- Data showing the structure and function align closely
Non-clinical work:
- Laboratory and animal data explaining how the product behaves
- Safety signals checked before human use
Clinical studies
- Trial designs focused on comparison, not reinvention
- Results covering safety, effectiveness, immune response, and exposure
- Justification if approvals are requested beyond studied indications
Safety systems
- A risk plan explaining how safety will be monitored after approval
- An overview of the company’s pharmacovigilance setup
Product information
- Draft SmPC for healthcare professionals
- Patient leaflet written in clear, understandable language
Where needed, environmental impact information is also added.
Step 3: EMA review and questions
Once submitted, the file goes through centralized assessment. The review is structured, but not silent.
Expect:
- Rounds of questions
- Requests for clarification
- Follow-up discussions on data gaps
This back-and-forth is normal and often decisive.
Step 4: Approval Decision
If the EMA is satisfied that:
- Biologic/Biosimilar product matches the reference biologic closely
- Risks are understood and manageable
- Quality is consistent
A central marketing authorisation is granted. That single approval opens access across the EU.
Biologics/Biosimilar Registration Applicable Fees in EU
Typically, it takes about 11 months for obtaining market authorization of biologics and biosimilars.
Extrapolation of Indications: The EU allows for the concept of extrapolation, where a biosimilar can be approved for an indication that was not directly studied in clinical trials if scientific justification is provided and the mechanism of action is well-understood.
Biologics & Biosimilars Labeling Requirements in the EU
In EU, biologics and biosimilars follow the same labeling rules that apply to other prescription medicines. What changes is the level of attention given to identification and traceability.
- The pack must clearly show the medicine name, its strength, and the form it comes in, such as a vial or pre-filled syringe.
- Both the brand name and the international non-proprietary name (INN) appear together.
For biosimilars, the INN is the same as the original product. - A batch or lot number is always required. This is critical for biological medicines and cannot be omitted.
- The company holding the marketing authorisation must be named on the label, along with its address.
- Expiry date and storage instructions must be easy to find. This often includes temperature limits.
- Some products need extra wording. Examples include restrictions on how the medicine is used or handled.
- Every product must include a patient leaflet. This explains, in plain language:
- what the medicine is for
- how it is given
- what side effects may occur
- how it should be stored
- Doctors and pharmacists rely on the Summary of Product Characteristics (SmPC). The wording in the SmPC must match what appears on the label and leaflet.
- For biosimilars, the label cannot suggest the product is better or worse than the reference biologic.
- Before a product reaches the market, all label text is reviewed and approved by the EMA and translated for each country where it is sold.
Post-Marketing Surveillance in EU (Biologics & Biosimilars)
Once a biologic or biosimilar is approved in Europe, the real responsibility begins. Regulators expect companies to stay alert to what happens after patients start using the product at scale. This is not optional, and it is not passive.
After approval in Europe, medicines are followed through the pharmacovigilance system. There isn’t a second PMS structure running in parallel. What matters is how the product behaves once it reaches everyday clinical use.
What companies are expected to do after launch
After authorisation, the marketing authorisation holder must continuously collect safety information from multiple sources. These include reports from healthcare professionals, patient complaints, published medical literature, and data coming through EU reporting systems.
All of this activity has to be organised under a documented setup known as the Pharmacovigilance System Master File (PSMF). Regulators may ask to review this file at any time, so it must reflect how safety monitoring is actually being done — not just how it was planned.
How safety concerns are handled
Safety data is reviewed on an ongoing basis. When required, companies submit Periodic Safety Update Reports (PSURs) that summarise new findings and reassess benefit versus risk.
If new risks emerge, regulators may ask for changes to labeling, additional warnings, or tighter controls. In rare cases, market restrictions or withdrawal can follow.
Traceability is critical for biologics
With biologics and biosimilars, product identification matters more than it does for small-molecule drugs.
When a safety issue is reported, regulators expect to see:
- Brand name, not just the substance name
- Batch or lot number, whenever available
Without this information, it becomes difficult to understand whether a problem relates to a specific product, a batch, or the wider class.
Conclusion
EU rules for biologics and biosimilars don’t leave much room for guesswork. Most delays come from small decisions taken too late. This is where experienced EU regulatory affairs support matters. Artixio works with teams that want clarity before committing. If you’re planning the next phase, a discussion helps.
Talk to Artixio about your biologics or biosimilars product submission. Email us at info@artixio.com!